* 泰国富豪谢氏家族旗下制药公司--中国生物制药1177.HK周三早盘一度升3%，TQH2722注射液新药上市申请获得受理。
* 该公司公告称，附属公司正大天晴药业集团自主研发的国家1类创新药TQH2722注射液“IL4Rα单抗”已向中国国家药品监督管理局药品审评中心（CDE）递交新药上市申请并获得受理，用于外用药控制不佳或不适合外用药治疗的成人中重度特应性皮炎$(AD)$。
* 中国生物制药今年迄今跌10.2%，同期恒生指数.HSI累跌3.9%。
* 恒生生物科技指数.HSBIO盘中跌0.3%。（完）
更多股市简讯请点选CN-CMN-HOT
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.